Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJKWMA)

Drug Name
Tanezumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Cancer related pain MG30 Phase 3 [1]
Chronic low back pain MG30.02 Phase 3 [2]
Neuropathic pain 8E43.0 Phase 3 [2]
Osteoarthritis FA00-FA05 Phase 3 [2]
Pain MG30-MG3Z Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMJKWMA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Nerve growth factor (NGF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fasinumab DM5PRLA Chronic low back pain MG30.02 Phase 3 [2]
SAR164877 DMOJLCV Pain MG30-MG3Z Phase 2/3 [3]
CERE-110 DMNW5I9 Alzheimer disease 8A20 Phase 2 [4]
CXB-909 DMUGMFN Neurodegenerative disorder 8A20-8A23 Phase 1/2 [5]
ABT-110 DM1F50I Chronic pain MG30 Phase 1 [3]
NsG-0202 DM1ITDN Alzheimer disease 8A20 Phase 1 [5]
MEDI-578 DMPW21Z Pain MG30-MG3Z Phase 1 [3]
Nerve growth factor DMHYQ8K Alzheimer disease 8A20 Terminated [6]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nerve growth factor (NGF) TTDN3LF NGF_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8415).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
4 CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7.
5 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.